Free Consultation

Office Locations

The Cochran Firm Legal Blog

With Office Locations Nationwide

Wednesday, May 5, 2010

Glaxo Suspends ‘Red Wine’ Drug Trial

In recent years, much attention has been given to reports that red wine offers health benefits. But safety concerns have prompted GlaxoSmithKline to suspend a clinical trial of a drug that mimics a health-boosting compound found in red wine, raising concern over the possibility of personal injury.

The substance SRT501 is a proprietary form of resveratrol, found in grapes and red wine and thought to offer health benefits, among them preventing heart disease and potentially slowing the aging process.

In 2008, Glaxo acquired the rights to SRT501 when it bought biotech Sirtris Pharmaceuticals. The clinical trial, testing the addition of SRT501 to the cancer drug Velcade for use by people with multiple myeloma, was suspended this week following, in the company’s words, “unexpected safety events.” The testing began in March 2009 and was to have continued into this December.

The dangers of defective consumer products are manifold, and pharmaceutical products in particular can have effects that may not even be noticed until years later. And if injury or death result, the people who suffer the consequences deserve to have their interests looked after.

At The Cochran Firm, we take very seriously the responsibility of assisting people who may have sustained a pharmaceutical injury caused by defective drugs. If you are concerned that you are one of these people, we urge you to please contact us for a free, confidential consultation.


posted by Benjamin A. Irwin at 9:52 AM

1.800.THE FIRM | 1.800.843.3476

The Cochran Firm handles Civil Litigation and Criminal Defense claims for clients throughout the United States of America. The information on this website does not constitute legal advice nor form an attorney-client relationship.Please contact The Cochran Firm today to schedule a free consultation.

Site Design, Development and Optimization by Page 1 Solutions | © - | Disclaimer